Avalyn Pharma Inc. AVLN
—
28.08
(0.47)
(1.65%)
as of 25 Sep
- Market cap
- $1.3B
- P/E
- 0.0×
Follow AVLN
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
33.12 | 11.03 | 10.19 | — |
+1 more quarter Free account |
Net Debt/EBITDA |
10.77 | 3.86 | 0.00 | 0.00 | |
Debt/Assets |
3.48% | 10.92% | 0.00% | 0.00% | |
Debt/Equity |
0.04 | (0.06) | 0.00 | 0.00 | |
Asset Turnover |
0.00 | — | — | — | |
Operating CF/Net income |
0.90 | 1.11 | — | 1.03 | |
Capex/Depreciation |
5.08 | 1.88 | — | 0.00 | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(0.89) | (24.55) | — | (18.07) | |
Cash per Share |
11.89 | 100.05 | 0.00 | 0.00 | |
Shareholders Equity per Share |
13.43 | (214.71) | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
13.43 | (214.71) | 0.00 | 0.00 | |
Free Cash Flow |
(26.34) | (30.21) | — | (20.70) | |
Working Capital |
347.18 | 118.20 | 129.47 | — | |
Capital Expenditures |
(0.27) | (0.32) | — | 0.00 | |
Net Current Asset Value |
330.89 | (269.92) | (243.98) | 0.00 | |
| Other line items | |||||
Quick Ratio |
32.60 | 10.45 | 9.82 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(0.88) | (24.29) | — | (18.07) | |
Capex per Share |
(0.01) | (0.26) | — | 0.00 | |
Average Assets |
212.72 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | — | 0.00% |
Columns are period end dates